サンプル依頼リスト カート
  • English
  • Korean
表紙：高脂血症治療薬の世界市場、規模調査＆予測、薬剤クラス別、地域別分析、2023～2030年
市場調査レポート
商品コード
1381671

高脂血症治療薬の世界市場、規模調査＆予測、薬剤クラス別、地域別分析、2023～2030年

Global Hyperlipidemia Drugs Market Size study & Forecast, by Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, Combination, Miscellaneous) and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
高脂血症治療薬の世界市場、規模調査＆予測、薬剤クラス別、地域別分析、2023～2030年
出版日: 2023年10月20日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

高脂血症治療薬は、脂質低下薬または脂質低下剤とも呼ばれ、血液中の脂質（脂肪）、特にコレステロールとトリグリセリドの高値を管理・治療するために使用される薬です。

高脂血症は、脂質レベルの上昇を特徴とする病態であり、心臓発作や脳卒中などの心血管疾患のリスク上昇につながる可能性があります。高脂血症治療薬市場は、心血管疾患の有病率上昇や世界の高脂血症有病率上昇などの要因により拡大しています。

高脂血症の有病率の上昇は、主に不健康なライフスタイル、座りがちな生活習慣、食生活の乱れに起因しており、脂質低下薬の需要を牽引しています。世界保健機関（WHO）は、高コレステロール血症が年間260万人以上の死亡原因になっていると推定しています。さらに、高コレステロールとして知られる高脂血症は、心臓病や脳卒中などの心血管疾患の重大な危険因子でもあります。世界的に心血管疾患の有病率が上昇していることが、高脂血症治療薬の成長を促進する要因となっています。米国心臓病学会（American College of Cardiology）の報告によると、2021年には695万人であった心血管疾患が、2030年には約2,900万人になるといわれています。2020年には、世界中で2億4,410万人が虚血性心疾患を抱えています。このように、心血管疾患の有病率の上昇が市場成長の原動力となっています。さらに、医薬品開発に関する臨床試験の増加や医療支出の増加が、市場成長の新たな機会を生み出しています。しかし、さまざまな治療法の利用可能性、副作用、安全性への懸念が、2023～2030年の予測期間を通じて市場成長を阻害しています。

高脂血症治療薬の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、主要市場参入企業の優位性、心血管疾患の有病率の上昇、医薬品開発の進展、臨床試験数の増加、同地域の医療支出により、2022年の市場を独占しました。一方、アジア太平洋は、心臓疾患の有病率の上昇、医療支出の増加、医療支出の増加、同地域における政府の積極的な参加などの要因によって、著しい速度で成長すると予測されています。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 高脂血症治療薬の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 高脂血症治療薬の世界市場力学

  • 高脂血症治療薬市場の影響分析（2020年～2030年）
    • 市場促進要因
      • 心血管疾患の有病率の上昇
      • 世界の高脂血症有病率の上昇
    • 市場の課題
      • さまざまな治療法の入手可能性
      • 副作用と安全性への懸念
    • 市場機会
      • 医薬品開発に関する臨床試験の増加
      • 医療支出の増加

第4章 高脂血症治療薬の世界市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 高脂血症治療薬の世界市場：薬剤クラス別

  • 市場スナップショット
  • 高脂血症治療薬の世界市場：薬剤クラス別、実績・ポテンシャル分析
  • 高脂血症治療薬の世界市場：薬剤クラス別、推定・予測、2020～2030年
  • 高脂血症治療薬の世界市場、サブセグメント別分析
    • スタチン
    • 胆汁酸分泌抑制薬
    • コレステロール吸収阻害薬
    • 線維酸誘導体
    • PCSK9阻害剤
    • 配合剤
    • その他

第6章 高脂血症治療薬の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • 高脂血症治療薬の世界市場、地域別市場スナップショット
  • 北米
    • 米国
      • 薬剤クラス別、推定・予測、2020～2030年
    • カナダ
  • 欧州の高脂血症治療薬市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他の欧州
  • アジア太平洋の高脂血症治療薬市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他のアジア太平洋
  • ラテンアメリカの高脂血症治療薬市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他の中東およびアフリカ

第7章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Amgen Inc.
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
    • AstraZeneca PLC
    • Daiichi Sankyo Company Limited
    • Eli Lilly and Company
    • Esperion Therapeutics Inc
    • GlaxoSmithKline Pharmaceuticals Limited（GlaxoSmithKline Plc）
    • Immuron Limited
    • Ionis Pharmaceuticals Inc.
    • Merck & Co. Inc.
    • Sanofi S.A.

第8章 調査プロセス

  • 調査プロセス
    • データ鉱業
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Hyperlipidemia Drugs Market, report scope
  • TABLE 2. Global Hyperlipidemia Drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Hyperlipidemia Drugs Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
  • TABLE 4. Global Hyperlipidemia Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 5. Global Hyperlipidemia Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 6. Global Hyperlipidemia Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Hyperlipidemia Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Hyperlipidemia Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Hyperlipidemia Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Hyperlipidemia Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Hyperlipidemia Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Hyperlipidemia Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Hyperlipidemia Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. U.S. Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. U.S. Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 16. U.S. Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 17. Canada Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 18. Canada Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20. UK Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 21. UK Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23. Germany Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 24. Germany Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26. France Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 27. France Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29. Italy Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 30. Italy Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32. Spain Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 33. Spain Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35. RoE Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 36. RoE Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38. China Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 39. China Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41. India Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 42. India Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44. Japan Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 45. Japan Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47. South Korea Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 48. South Korea Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50. Australia Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 51. Australia Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53. RoAPAC Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 54. RoAPAC Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56. Brazil Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 57. Brazil Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59. Mexico Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 60. Mexico Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62. RoLA Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 63. RoLA Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65. Saudi Arabia Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 66. South Africa Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. RoMEA Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68. List of secondary sources, used in the study of global Hyperlipidemia Drugs Market
  • TABLE 69. List of primary sources, used in the study of global Hyperlipidemia Drugs Market
  • TABLE 70. Years considered for the study
  • TABLE 71. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Hyperlipidemia Drugs Market, research methodology
  • FIG 2. Global Hyperlipidemia Drugs Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Hyperlipidemia Drugs Market, key trends 2022
  • FIG 5. Global Hyperlipidemia Drugs Market, growth prospects 2023-2030
  • FIG 6. Global Hyperlipidemia Drugs Market, porters 5 force model
  • FIG 7. Global Hyperlipidemia Drugs Market, pest analysis
  • FIG 8. Global Hyperlipidemia Drugs Market, value chain analysis
  • FIG 9. Global Hyperlipidemia Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Hyperlipidemia Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Hyperlipidemia Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Hyperlipidemia Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Hyperlipidemia Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Hyperlipidemia Drugs Market, regional snapshot 2020 & 2030
  • FIG 15. North America Hyperlipidemia Drugs Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Hyperlipidemia Drugs Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Hyperlipidemia Drugs Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Hyperlipidemia Drugs Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Hyperlipidemia Drugs Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Hyperlipidemia drugs, also known as lipid-lowering drugs or lipid-lowering agents, are medications used to manage and treat high levels of lipids (fats) in the blood, particularly cholesterol and triglycerides. Hyperlipidemia is a condition characterized by elevated levels of lipids, which can lead to an increased risk of cardiovascular diseases such as heart attacks and strokes. The Hyperlipidemia Drugs market is expanding because of factors such as the rising prevalence of cardiovascular diseases and the rise in the prevalence of hyperlipidemia across the globe.

The rising prevalence of hyperlipidemia, primarily attributed to unhealthy lifestyles, sedentary habits, and poor dietary choices, has driven the demand for lipid-lowering medications. The World Health Organisation (WHO) estimates that hypercholesterolemia causes more than 2.6 million deaths annually. Additionally, Hyperlipidemia, also known as high cholesterol, is a significant risk factor for cardiovascular diseases such as heart disease and stroke. The rising prevalence of cardiovascular disease worldwide has been a driving factor in the growth of Hyperlipidemia Drugs. The American College of Cardiology reports that by 2030, there would be around 29 million Americans with a diagnosis of cardiovascular disease, up from 6.95 million in the year 2021. In 2020, 244.1 million people worldwide were living with ischemic heart disease. Thus, the rising prevalence of cardiovascular diseases is driving the market growth. In addition, increasing clinical trials on drug development and rising healthcare expenditure are creating new opportunities for market growth. However, the availability of different treatments, adverse effects, and safety concerns stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Hyperlipidemia Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of key market players, rising prevalence of cardiovascular disease, advancement in drug development, rising number of clinical trials activities and healthcare expenditure in the region. Whereas, Asia Pacific is projected to grow a significant rate owing to factors such as the rising prevalence of heart diseases, rising healthcare expenditure, rising healthcare expenditure, active participation of government in the region.

Major market player included in this report are:

  • Amgen Inc.
  • AstraZeneca PLC
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Esperion Therapeutics Inc
  • GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
  • Immuron Limited
  • Ionis Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Sanofi S.A.

Recent Developments in the Market:

  • In January 2023, AstraZeneca entered signed an agreement to acquire CinCor Pharma, Inc., a clinical-stage biopharmaceutical business based in the US that specializes in developing innovative medications for chronic kidney disease and safe, uncontrolled hypertension.
  • In May 2022, Zydus Lifesciences launched its bempedoic acid drug under the trade name Bemdac in India to treat high levels of harmful cholesterol.

Global Hyperlipidemia Drugs Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Drug Class, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Miscellaneous

By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • ROE
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Hyperlipidemia Drugs Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Hyperlipidemia Drugs Market, by Drug Class, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Hyperlipidemia Drugs Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Hyperlipidemia Drugs Market Dynamics

  • 3.1. Hyperlipidemia Drugs Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of cardiovascular diseases
      • 3.1.1.2. Rise in prevalence of hyperlipidemia across the globe
    • 3.1.2. Market Challenges
      • 3.1.2.1. Availability of different treatments
      • 3.1.2.2. Adverse effects and safety concerns
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing clinical trials on drug development
      • 3.1.3.2. Rising healthcare expenditure

Chapter 4. Global Hyperlipidemia Drugs Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Hyperlipidemia Drugs Market, by Drug Class

  • 5.1. Market Snapshot
  • 5.2. Global Hyperlipidemia Drugs Market by Drug Class, Performance - Potential Analysis
  • 5.3. Global Hyperlipidemia Drugs Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
  • 5.4. Hyperlipidemia Drugs Market, Sub Segment Analysis
    • 5.4.1. Statins
    • 5.4.2. Bile Acid Sequestrants
    • 5.4.3. Cholesterol Absorption Inhibitors
    • 5.4.4. Fibric Acid Derivatives
    • 5.4.5. PCSK9 Inhibitors
    • 5.4.6. Combination
    • 5.4.7. Miscellaneous

Chapter 6. Global Hyperlipidemia Drugs Market, Regional Analysis

  • 6.1. Top Leading Countries
  • 6.2. Top Emerging Countries
  • 6.3. Hyperlipidemia Drugs Market, Regional Market Snapshot
  • 6.4. North America Hyperlipidemia Drugs Market
    • 6.4.1. U.S. Hyperlipidemia Drugs Market
      • 6.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
    • 6.4.2. Canada Hyperlipidemia Drugs Market
  • 6.5. Europe Hyperlipidemia Drugs Market Snapshot
    • 6.5.1. U.K. Hyperlipidemia Drugs Market
    • 6.5.2. Germany Hyperlipidemia Drugs Market
    • 6.5.3. France Hyperlipidemia Drugs Market
    • 6.5.4. Spain Hyperlipidemia Drugs Market
    • 6.5.5. Italy Hyperlipidemia Drugs Market
    • 6.5.6. Rest of Europe Hyperlipidemia Drugs Market
  • 6.6. Asia-Pacific Hyperlipidemia Drugs Market Snapshot
    • 6.6.1. China Hyperlipidemia Drugs Market
    • 6.6.2. India Hyperlipidemia Drugs Market
    • 6.6.3. Japan Hyperlipidemia Drugs Market
    • 6.6.4. Australia Hyperlipidemia Drugs Market
    • 6.6.5. South Korea Hyperlipidemia Drugs Market
    • 6.6.6. Rest of Asia Pacific Hyperlipidemia Drugs Market
  • 6.7. Latin America Hyperlipidemia Drugs Market Snapshot
    • 6.7.1. Brazil Hyperlipidemia Drugs Market
    • 6.7.2. Mexico Hyperlipidemia Drugs Market
  • 6.8. Middle East & Africa Hyperlipidemia Drugs Market
    • 6.8.1. Saudi Arabia Hyperlipidemia Drugs Market
    • 6.8.2. South Africa Hyperlipidemia Drugs Market
    • 6.8.3. Rest of Middle East & Africa Hyperlipidemia Drugs Market

Chapter 7. Competitive Intelligence

  • 7.1. Key Company SWOT Analysis
    • 7.1.1. Company 1
    • 7.1.2. Company 2
    • 7.1.3. Company 3
  • 7.2. Top Market Strategies
  • 7.3. Company Profiles
    • 7.3.1. Amgen Inc.
      • 7.3.1.1. Key Information
      • 7.3.1.2. Overview
      • 7.3.1.3. Financial (Subject to Data Availability)
      • 7.3.1.4. Product Summary
      • 7.3.1.5. Recent Developments
    • 7.3.2. AstraZeneca PLC
    • 7.3.3. Daiichi Sankyo Company Limited
    • 7.3.4. Eli Lilly and Company
    • 7.3.5. Esperion Therapeutics Inc
    • 7.3.6. GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
    • 7.3.7. Immuron Limited
    • 7.3.8. Ionis Pharmaceuticals Inc.
    • 7.3.9. Merck & Co. Inc.
    • 7.3.10. Sanofi S.A.

Chapter 8. Research Process

  • 8.1. Research Process
    • 8.1.1. Data Mining
    • 8.1.2. Analysis
    • 8.1.3. Market Estimation
    • 8.1.4. Validation
    • 8.1.5. Publishing
  • 8.2. Research Attributes
  • 8.3. Research Assumption